[go: up one dir, main page]

NO932437D0 - Fusjonsproteiner med blandet spesifitet - Google Patents

Fusjonsproteiner med blandet spesifitet

Info

Publication number
NO932437D0
NO932437D0 NO932437A NO932437A NO932437D0 NO 932437 D0 NO932437 D0 NO 932437D0 NO 932437 A NO932437 A NO 932437A NO 932437 A NO932437 A NO 932437A NO 932437 D0 NO932437 D0 NO 932437D0
Authority
NO
Norway
Prior art keywords
fusion proteins
patient
cellular adhesion
administered
inhibit
Prior art date
Application number
NO932437A
Other languages
English (en)
Other versions
NO313241B1 (no
NO932437L (no
Inventor
Alejandro A Aruffo
Peter S Linsley
Jeffery A Ledbetter
Nitin K Damle
Jr Perry H Fell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO932437D0 publication Critical patent/NO932437D0/no
Publication of NO932437L publication Critical patent/NO932437L/no
Publication of NO313241B1 publication Critical patent/NO313241B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19932437A 1991-01-24 1993-07-05 Fusjonsproteiner med blandet spesifisitet NO313241B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/645,522 US5709859A (en) 1991-01-24 1991-01-24 Mixed specificity fusion proteins
PCT/US1992/000616 WO1992012994A1 (en) 1991-01-24 1992-01-24 Mixed specificity fusion proteins

Publications (3)

Publication Number Publication Date
NO932437D0 true NO932437D0 (no) 1993-07-05
NO932437L NO932437L (no) 1993-09-17
NO313241B1 NO313241B1 (no) 2002-09-02

Family

ID=24589356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19932437A NO313241B1 (no) 1991-01-24 1993-07-05 Fusjonsproteiner med blandet spesifisitet

Country Status (18)

Country Link
US (1) US5709859A (no)
EP (1) EP0568645B1 (no)
JP (1) JP3394534B2 (no)
KR (1) KR100259061B1 (no)
AT (1) ATE195254T1 (no)
AU (1) AU648398B2 (no)
CA (1) CA2099779C (no)
DE (1) DE69231333T2 (no)
DK (1) DK0568645T3 (no)
ES (1) ES2148173T3 (no)
FI (1) FI109203B (no)
GR (1) GR3034524T3 (no)
IE (1) IE920202A1 (no)
IL (1) IL100731A (no)
NO (1) NO313241B1 (no)
NZ (1) NZ241357A (no)
WO (1) WO1992012994A1 (no)
ZA (1) ZA92467B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) * 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
AU694933B2 (en) * 1993-01-25 1998-08-06 Dana-Farber Cancer Institute, Inc. Chimeric L- and P-selectin by exchange of domains - uses thereof
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
AU3193399A (en) 1998-03-23 1999-10-18 Genentech Inc. Method of selection for genes encoding secreted and transmembrane proteins
MXPA00010070A (es) * 1998-04-15 2004-03-10 Lexigen Pharm Corp Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
WO2000058501A2 (en) * 1999-03-26 2000-10-05 The Wistar Institute Novel genetic suppressor elements and methods of making the same
PT1187852E (pt) * 1999-05-19 2007-11-14 Merck Patent Gmbh Expressão e exportação de proteínas interferão-alfa na forma de proteínas de fusão com fc
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
CA2412845C (en) * 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
EP1418944A2 (en) * 2001-05-16 2004-05-19 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
KR100988180B1 (ko) 2001-12-04 2010-10-18 메르크 파텐트 게엠베하 조절된 선택성을 갖는 면역시토카인
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
ES2346205T3 (es) * 2002-12-17 2010-10-13 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
RU2412945C2 (ru) * 2004-05-11 2011-02-27 Эбдженомикс Кооператиф У.А. Эпитопы, индуцирующие гибель т-клеток
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ATE465176T1 (de) * 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
JP5740076B2 (ja) 2005-07-25 2015-06-24 エマージェント・プロダクト・ディベロップメント・シアトル・エルエルシー Ｃｄ３７特異的及びｃｄ２０特異的結合分子を用いたｂ細胞の減少
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2654317A1 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA2719924C (en) 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
KR20120030383A (ko) * 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
KR101632312B1 (ko) * 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
WO2011130533A1 (en) 2010-04-16 2011-10-20 Centocor Ortho Biotech Inc. Engineered plant cysteine proteases and their uses
CA2812389C (en) 2010-09-27 2019-12-31 John Kehoe Antibodies binding human collagen ii
NZ609567A (en) 2010-11-05 2015-05-29 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
EP3925978A1 (en) 2011-06-13 2021-12-22 AltruBio Inc. Anti-psgl-1 antibodies and uses thereof
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
MX2018004600A (es) * 2015-10-15 2019-09-04 Celularity Inc Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0606518B1 (en) * 1988-09-28 2003-07-30 Dana Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0585963A1 (en) * 1989-05-23 1994-03-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to CMP-170 antigen on activated endothelial cells
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules

Also Published As

Publication number Publication date
ZA92467B (en) 1992-09-30
FI933292L (fi) 1993-07-21
KR930703008A (ko) 1993-11-29
AU648398B2 (en) 1994-04-21
DE69231333T2 (de) 2001-01-18
NZ241357A (en) 1994-04-27
EP0568645A4 (en) 1994-09-28
AU1339192A (en) 1992-08-27
DE69231333D1 (de) 2000-09-14
IE920202A1 (en) 1992-07-29
EP0568645A1 (en) 1993-11-10
DK0568645T3 (da) 2000-09-18
EP0568645B1 (en) 2000-08-09
ES2148173T3 (es) 2000-10-16
FI109203B (fi) 2002-06-14
CA2099779A1 (en) 1992-07-25
NO313241B1 (no) 2002-09-02
FI933292A0 (fi) 1993-07-21
GR3034524T3 (en) 2000-12-29
NO932437L (no) 1993-09-17
CA2099779C (en) 2002-03-19
ATE195254T1 (de) 2000-08-15
KR100259061B1 (ko) 2000-07-01
IL100731A (en) 1997-07-13
JPH06505388A (ja) 1994-06-23
IL100731A0 (en) 1992-09-06
JP3394534B2 (ja) 2003-04-07
US5709859A (en) 1998-01-20
WO1992012994A1 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
NO932437D0 (no) Fusjonsproteiner med blandet spesifitet
Fernandez-Botran et al. A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice.
EP0673255A4 (en) MONOCLONAL ANTIBODY, WHICH SPECIFICALLY BINDS TO VASCULARIZED TUMOR DOTHELIUM AND USES THEREOF.
DK0554344T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af en malign tumor
ES2186701T3 (es) Proteinas de fusion terapeuticas con base de anticuerpos con factor 4 de plaquetas.
BR9707379A (pt) Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
DE10075010I1 (de) Fusionsproteine mit immunglobulinanteilen ihre Herstellung und Verwendung
DE59209650D1 (de) Monoklonale antikörper gegen c-kit
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
Tomasini et al. On the identity of vitronectin and S-protein: immunological crossreactivity and functional studies
KR950701390A (ko) 비타민 B12/ 트랜스코발라민 II 수용체에 대한 항-수용체 제제(Anti-receptor agents to the vitamin B12/ transcobalamin II receptor)
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
Kürschner et al. Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
Neumaier et al. Delineation of four carcinoembryonic antigen (CEA) related antigens in normal plasma by transblot studies using monoclonal anti-CEA antibodies with different epitope specificities
Suzuki et al. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody
Ocklind et al. Different cell surface glycoproteins are involved in cell—cell and cell—collagen adhesion of rat hepatocytes
Nagata et al. Distribution of the low molecular weight form of eukaryotic elongation factor 1 in various tissues
ATE190353T1 (de) Icams konstante domäne wasserlöslichen fusionsproteine, immunoglobulin
Jacques et al. Biochemical study of a recombinant soluble interleukin-2 receptor. Evidence for a homodimeric structure
Hannestad et al. Multiple M-components in a single individual-iI studies on urinary Fab μ like fragments in macroglobulinema
Sorg Use of a radioactive double labeling technique in the chemical analysis of the mediators of cellular immunity
Stein et al. Myeloma producing nonsecretory IgM and secretory IgG
Vedeler et al. Peripheral nerve CR1 limit complement-mediated haemolysis

Legal Events

Date Code Title Description
MK1K Patent expired